Also known as: AIDS
AIDS is the advanced stage of HIV infection characterized by severe immune suppression and susceptibility to opportunistic infections and cancers.
Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.
A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07579247 |
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07032363 |
Implementing Depression and Adherence Treatment |
RECRUITING | NA |
| NCT06585631 |
The Collaborative Care PrTNER Study |
RECRUITING | NA |
| NCT06045923 |
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV |
TERMINATED | |
| NCT03670316 |
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care |
COMPLETED | PHASE4 |
